Bard Financial Services Inc. Raises Holdings in GSK plc (NYSE:GSK)

Bard Financial Services Inc. increased its position in GSK plc (NYSE:GSK - Free Report) by 491.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 41,045 shares of the pharmaceutical company's stock after purchasing an additional 34,100 shares during the quarter. Bard Financial Services Inc.'s holdings in GSK were worth $1,521,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Versant Capital Management Inc boosted its position in GSK by 2,816.7% during the 4th quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company's stock valued at $26,000 after acquiring an additional 676 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of GSK by 271.8% during the 3rd quarter. Larson Financial Group LLC now owns 885 shares of the pharmaceutical company's stock valued at $32,000 after purchasing an additional 647 shares during the last quarter. BKM Wealth Management LLC purchased a new stake in shares of GSK during the 4th quarter valued at $32,000. Jones Financial Companies Lllp lifted its holdings in shares of GSK by 62.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company's stock valued at $48,000 after purchasing an additional 509 shares during the last quarter. Finally, Princeton Global Asset Management LLC lifted its holdings in shares of GSK by 54.3% during the 4th quarter. Princeton Global Asset Management LLC now owns 1,515 shares of the pharmaceutical company's stock valued at $56,000 after purchasing an additional 533 shares during the last quarter. Institutional investors own 15.74% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently commented on GSK. Citigroup upgraded GSK from a "neutral" rating to a "buy" rating in a report on Tuesday, February 13th. Guggenheim upgraded GSK from a "neutral" rating to a "buy" rating in a research note on Monday, March 4th. Finally, Morgan Stanley started coverage on GSK in a research note on Tuesday, January 23rd. They issued an "equal weight" rating for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, GSK currently has a consensus rating of "Moderate Buy".

GSK Stock Performance

Shares of NYSE GSK traded down $0.13 during trading on Tuesday, reaching $44.46. 3,474,957 shares of the company traded hands, compared to its average volume of 3,501,302. The firm's fifty day simple moving average is $42.36 and its 200 day simple moving average is $39.91. The stock has a market cap of $92.14 billion, a P/E ratio of 16.16, a PEG ratio of 1.94 and a beta of 0.65. GSK plc has a 12-month low of $33.33 and a 12-month high of $45.92. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.15.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be paid a dividend of $0.3762 per share. The ex-dividend date is Thursday, May 16th. This represents a $1.50 dividend on an annualized basis and a dividend yield of 3.38%. This is a positive change from GSK's previous quarterly dividend of $0.36. GSK's dividend payout ratio (DPR) is presently 53.26%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.